For me it's not a significant consideration at this point. With green lights now in US and EU (today) - its the downstream projections that will matter most - market and indication expansions.
The key for me is that they have moved beyond the "FDA issue" of 2013...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.